Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip
about
Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicityPhysicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs)Targeting heat shock proteins to modulate α-synuclein toxicityMolecular chaperones and co-chaperones in Parkinson diseaseTargeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseasesHsp72 (HSPA1A) Prevents Human Islet Amyloid Polypeptide Aggregation and Toxicity: A New Approach for Type 2 Diabetes Treatmentn-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's diseaseStructure and function of Hip, an attenuator of the Hsp70 chaperone cycleLegal but lethal: functional protein aggregation at the verge of toxicityIdentification of bilateral changes in TID1 expression in the 6-OHDA rat model of Parkinson's diseaseIntrinsically disordered proteins as molecular shieldsHeat shock proteins in neurodegenerative disorders and agingThe Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative DiseasesWatching worms whither: modeling neurodegeneration in C. elegans.Hsp70 and its molecular role in nervous system diseasesCellular strategies of protein quality control.Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathyHsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycleHsp70 oligomerization is mediated by an interaction between the interdomain linker and the substrate-binding domain.A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseasesChaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotypeProtein solubility and protein homeostasis: a generic view of protein misfolding disorders.pH-induced molecular shedding drives the formation of amyloid fibril-derived oligomersMolecular chaperones in Parkinson's disease--present and futureRational design of antibodies targeting specific epitopes within intrinsically disordered proteins.Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers.Chaperone networks: tipping the balance in protein folding diseasesIdentification of protein interfaces between α-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p.Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradationThe C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation.Effects of α-synuclein overexpression in transgenic Caenorhabditis elegans strainsThe chaperonin CCT inhibits assembly of α-synuclein amyloid fibrils by a specific, conformation-dependent interaction.Basic mechanisms of neurodegeneration: a critical update.Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.Insights from Caenorhabditis elegans on the role of metals in neurodegenerative diseases.Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseasesActive immunization therapies for Parkinson's disease and multiple system atrophy.Targeting Hsp70: A possible therapy for cancer.Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.Identification of fibril-like tertiary contacts in soluble monomeric α-synuclein
P2860
Q26739032-F670CE69-3AC6-4376-A139-09F163CE193EQ26823798-F95D8BFD-2513-4080-A995-C2ED76E3FF7BQ26827066-C8896DAF-835A-4E88-807C-469324FD2EF9Q26828834-BF52FBDD-A3E2-43C6-AADE-A2D1ED44A99CQ26859909-87DCA98B-6567-4CA8-97EE-8A9345BC9BB1Q27321279-C79B2E9B-E4D7-41AC-9625-8A7476BE152FQ27334018-1195C276-9E29-4440-BA40-E813E169CE48Q27685147-5B8B11D7-F3DB-414D-A6FC-8EA9A028C1E8Q28084859-C9780E31-10C9-4BB3-8458-88DE8BC2779BQ28477415-F326F5B8-4275-436E-950F-12E5E9E2142EQ28910362-088138F9-16B7-4AA7-8ED9-CC4BE2C42972Q30414556-18010C75-4DC8-4A07-812C-F57994717FF0Q33692255-A1A190C4-0A2A-4749-8894-A15556A4AC3FQ33837857-31B016DC-42E5-4E02-9774-86A610EDE920Q34170760-C4581768-D1BB-4F05-ADCA-2D6A566D7213Q34199521-C9396426-DA75-47D5-ADAE-E7F243D27749Q34344053-F98447D2-DD60-479C-8293-A24C4D742236Q34352145-797940F9-9C97-49A0-B781-683CE1333A4FQ34808252-7E723850-3CEA-4A31-8D00-EA8372406E80Q35053633-2055A9F9-4B61-476B-8494-435207140DB2Q35285839-932D28AA-FB06-4B35-92F2-3B1B68B0470CQ35578436-51752BEC-73B7-43A9-B1CC-BA0B1AE4A866Q35590322-D1E74513-D65C-4704-97FC-E7ED4101E2BBQ35688796-FEF241EB-6B93-49D2-98BA-41E4A07B7220Q35961236-9F26356C-0587-4019-BAD7-1012D65A6A74Q36140162-11BC10BD-5625-4E9F-8E8C-55082758859AQ36194355-72BBCB79-1A70-49B8-9F03-10D07AD945E4Q36294832-5E64B99B-956C-46D0-AB45-959274BFDDF2Q36553586-960B35C9-54C3-4840-B570-1F4ACDB17647Q36926050-EE8FBA27-D82F-4635-8955-A0773DACAA53Q37098708-B17C20FC-131A-4D68-8870-24627B9031D1Q37593239-B1B75C74-45AB-448C-9AEF-13EC5D3B7E66Q37673274-8BB67000-67B7-4373-ABC5-A4D41E7027F2Q37799850-27FEE1EE-A509-4F1D-B4DD-0FDDEA2517EAQ37826364-23E28105-7A75-4244-AE7F-EF43DA47AA02Q38093796-E74785DF-D5B8-48FE-8054-8EE9A3028D23Q38564102-566150B1-A357-4C72-9CE3-C1113C5EF6DFQ38742944-D133360C-42A8-4C7D-BC8C-786BBFDDD510Q38927256-258036FD-866E-415E-821B-3CE622E5CF22Q42185349-3DE22F5A-0286-4297-8F58-96F9F2E35BEB
P2860
Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@ast
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@en
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@en-gb
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@nl
type
label
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@ast
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@en
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@en-gb
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@nl
altLabel
Chaperone proteostasis in Park ...... p70/α-synuclein complex by Hip
@en
prefLabel
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@ast
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@en
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@en-gb
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@nl
P2093
P2860
P50
P921
P3181
P356
P1433
P1476
Chaperone proteostasis in Park ...... alpha-synuclein complex by Hip
@en
P2093
Annemieke T van der Goot
August Andersson
Ellen A Nollen
Jannie de Jong
John Christodoulou
Rafael Fernández-Montesinos
P2860
P304
P3181
P356
10.1038/EMBOJ.2009.298
P407
P577
2009-12-02T00:00:00Z